Charles River Laboratories International, Inc. (CRL) Forecasted to Post Q1 2018 Earnings of $1.29 Per Share

Charles River Laboratories International, Inc. (NYSE:CRL) – Stock analysts at First Analysis reduced their Q1 2018 earnings per share estimates for shares of Charles River Laboratories International in a research note issued on Monday. First Analysis analyst T. Van. Fleet now forecasts that the medical research company will post earnings of $1.29 per share for the quarter, down from their previous estimate of $1.32. First Analysis also issued estimates for Charles River Laboratories International’s Q2 2018 earnings at $1.43 EPS, Q3 2018 earnings at $1.38 EPS and FY2018 earnings at $5.50 EPS.

Other equities research analysts have also issued research reports about the company. Jefferies Group reissued a “buy” rating and set a $120.00 price objective on shares of Charles River Laboratories International in a research note on Tuesday, September 12th. Robert W. Baird reissued a “buy” rating and set a $114.00 price objective on shares of Charles River Laboratories International in a research note on Friday, September 1st. Bank of America lowered their price target on Charles River Laboratories International from $117.00 to $115.00 and set a “buy” rating on the stock in a research report on Friday, November 10th. Zacks Investment Research upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $129.00 price target on the stock in a research report on Tuesday, October 24th. Finally, Argus started coverage on Charles River Laboratories International in a research report on Wednesday, December 13th. They set a “buy” rating and a $120.00 price target on the stock. Six investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $110.21.

Charles River Laboratories International (NYSE:CRL) traded up $1.29 during trading hours on Tuesday, reaching $109.74. The company had a trading volume of 368,400 shares, compared to its average volume of 378,073. The company has a market capitalization of $5,136.36, a price-to-earnings ratio of 21.31, a price-to-earnings-growth ratio of 1.73 and a beta of 0.89. Charles River Laboratories International has a 12 month low of $73.81 and a 12 month high of $119.05. The company has a quick ratio of 1.62, a current ratio of 1.88 and a debt-to-equity ratio of 1.13.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Thursday, November 9th. The medical research company reported $1.30 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.22 by $0.08. The company had revenue of $464.23 million during the quarter, compared to analyst estimates of $458.93 million. Charles River Laboratories International had a return on equity of 26.58% and a net margin of 10.72%. The firm’s quarterly revenue was up 9.0% on a year-over-year basis. During the same quarter last year, the company earned $1.18 earnings per share.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bridgewater Associates LP purchased a new position in shares of Charles River Laboratories International in the second quarter worth about $679,000. Prudential Financial Inc. increased its holdings in Charles River Laboratories International by 19.0% during the 2nd quarter. Prudential Financial Inc. now owns 425,860 shares of the medical research company’s stock valued at $43,076,000 after purchasing an additional 68,058 shares during the period. American Century Companies Inc. bought a new stake in Charles River Laboratories International during the 2nd quarter valued at approximately $292,000. State Street Corp boosted its position in Charles River Laboratories International by 2.3% during the 2nd quarter. State Street Corp now owns 1,268,308 shares of the medical research company’s stock valued at $128,288,000 after acquiring an additional 28,365 shares in the last quarter. Finally, Northern Trust Corp boosted its position in Charles River Laboratories International by 1.5% during the 2nd quarter. Northern Trust Corp now owns 436,860 shares of the medical research company’s stock valued at $44,188,000 after acquiring an additional 6,304 shares in the last quarter. Hedge funds and other institutional investors own 95.80% of the company’s stock.

In other news, insider Bradley Nixon Scharfe sold 1,000,000 shares of Charles River Laboratories International stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $0.27, for a total value of $270,000.00. Also, insider Davide Molho sold 6,165 shares of Charles River Laboratories International stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $110.00, for a total value of $678,150.00. The disclosure for this sale can be found here. In the last 90 days, insiders have acquired 10,500 shares of company stock worth $2,885 and have sold 1,056,776 shares worth $2,011,952. Company insiders own 2.20% of the company’s stock.

WARNING: This piece of content was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2017/12/20/charles-river-laboratories-international-inc-crl-forecasted-to-post-q1-2018-earnings-of-1-29-per-share.html.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Earnings History and Estimates for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply